Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

15.04.2020 | short review | Ausgabe 2/2020 Open Access

memo - Magazine of European Medical Oncology 2/2020

Ovarian cancer surgery

Game-changing innovations

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2020
Autoren:
Richard Schwameis, Valentina Paspalj, Marlene Kranawetter, Assoc. Prof. PD Dr. Stephan Polterauer
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

Surgery is a cornerstone of treatment in patients with ovarian cancer. In primary disease, patients should be carefully selected to undergo either primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery. The aim of every debulking surgery is complete tumour resection. Whilst thorough evaluation of the iliac and para-aortic lymph nodes is important, systematic lymphadenectomy may be omitted when lymph nodes seem unsuspicious. To date, surgical outcome seems to remain the most important prognostic factor in the treatment of patients with ovarian cancer and therefore patients should only be treated in high-volume centres that are able to perform complex multidisciplinary surgery. The role of debulking surgery in recurrent disease has yet to be defined.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2020

memo - Magazine of European Medical Oncology 2/2020 Zur Ausgabe